- March 15, 2022
- Newsletter
- 617-430-5616
Menu
Menu
Menu
Menu
Menu
Menu
Brand Name :
Savaysa,lixiana
Synonyms :
edoxaban
Class :
Factor Xa inhibitors
Dosage Forms & Strengths
Tablet
15mg,30mg,60mg
After 5-10 days of initial treatment with a parenteral anticoagulant:
60
mg
Orally
every day
Tablet
After 5-10 days of initial treatment:
≤60kg:30mg orally every day >60kg:60mg orally every day
Dose Adjustments
Renal impairment (PE/DVT)
15-50ml/min-30mg orally every day
>50ml/min-No dosage adjustment needed
Renal impairment (Atrial fibrillation)
CrCl<15ml/min: No data available
CrCl 15-50ml/min:30mg orally every
day
CrCl>50-95ml/min: Dosage adjustment not necessary
CrCl>95ml/min: Not recommended
may enhance the effects of the other by pharmacodynamic synergism
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the adverse effect of nonsteroidal anti-inflammatory agents
may increase the toxic effect of anti-platelet agents
may increase the toxic effect of aspirin
may have an increasingly adverse effect when combined with edoxaban
may increase the toxic effect of nonsteroidal anti-inflammatory agents
may increases the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the toxicity through anti-coagulation
may increase the toxicity of each other through anti coagulation
may decrease the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the toxicity of the other through anti coagulation
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may decrease the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the toxicity of the other through anti coagulation
edoxaban increases the effect of anticoagulants
edoxaban increases the effect of anticoagulants
edoxaban increases the effect of anticoagulants
edoxaban increases the effect of anticoagulants
edoxaban increases the effect of anticoagulants
lapatinib increases the level of effectiveness of edoxaban through P-glycoprotein MDR1 efflux transporter
may increase the anti-coagulant action of anti-coagulants
may enhance the toxicity of the other through anti coagulation
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may enhance the toxicity of the other through anti coagulation
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
may have an increasingly adverse effect when combined with Edoxaban
may have an increasingly adverse effect when combined with Edoxaban
may have an increasingly adverse effect when combined with Edoxaban
may have an increasingly adverse effect when combined with Edoxaban
may have an increasingly adverse effect when combined with Edoxaban
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
may decrease the therapeutic effect when combined with anticoagulants
It may enhance the effect when combined with lonafarnib by affecting the P-glycoprotein efflux transporter
antiplatelet agents increase the toxicity of edoxaban
antiplatelet agents increase the toxicity of edoxaban
may enhance the serum concentration
may increase the anticoagulant effect of Anticoagulants
Frequency defined:
1-10%
Anemia
Abnormal LFT
Rash
<1%
Lung disease
Fatal bleeding
Gastrointestinal bleeding
Major bleeding
Post-marketing reports
Headache
Dizziness
Abdominal pain
Pregnancy consideration: Insufficient data available
Pregnancy category: Not assigned
Lactation: The drug is not excreted in the breast milk
Pregnancy category:
Patient information leaflet
Generic Name: edoxaban
Pronounced: [e-DOX-a-ban]
Why do we use edoxaban?
It is used to treat Deep vein thrombosis (DVT), a form of the blood clot and pulmonary embolism
ADVERTISEMENT
